A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
- Gurney, Howard (Primary Chief Investigator)
- Cunningham, Jacob, (Research Assistant)
- Butala, Radhika, (Research Assistant)
Project: Other